RUNX1是T细胞急性淋巴细胞白血病中致癌性Myb和Myc增强子活性所必需的
该研究在Tal1/Lmo2/Rosa26-CreERT2Runx1f/f小鼠中通过他莫昔芬诱导Runx1缺失,发现Runx1缺失抑制体内小鼠白血病生长,且RUNX沉默触发人类T-ALL细胞凋亡。CBFβ-RUNX结合小分子抑制剂损害人类T-ALL细胞系和原代患者样本的生长。RUNX1缺陷改变TAL1和NOTCH1调控的关键基因子集(包括MYB和MYC)的表达,提示RUNX1具有致癌作用并可作为T-ALL的新治疗靶点。
要点
- Runx1缺失抑制体内小鼠白血病生长,RUNX沉默触发人类T-ALL细胞凋亡。
- CBFβ-RUNX结合小分子抑制剂损害人类T-ALL细胞系和原代患者样本的生长。
- RUNX1缺陷改变TAL1和NOTCH1调控的关键基因子集(包括MYB和MYC)的表达。
核心结论
- 这些研究提供遗传和药理学证据表明RUNX1具有致癌作用,并揭示RUNX1是T-ALL的新治疗靶点。
研究设计与样本
- 研究生成Tal1/Lmo2/Rosa26-CreERT2Runx1f/f小鼠,在载体或他莫昔芬存在下检查白血病进展。
- 研究在人类T-ALL细胞中进行RUNX沉默实验,并测试CBFβ-RUNX结合小分子抑制剂对细胞系和原代患者样本生长的影响。
主要发现
- Runx1缺失抑制体内小鼠白血病生长,RUNX沉默触发人类T-ALL细胞凋亡。
- CBFβ-RUNX结合小分子抑制剂损害人类T-ALL细胞系和原代患者样本的生长。
- RUNX1缺陷改变TAL1和NOTCH1调控的关键基因子集(包括MYB和MYC)的表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gene encoding the RUNX1 transcription factor is mutated in a subset of T-cell acute lymphoblastic leukemia (T-ALL) patients, and RUNX1 mutations are associated with a poor prognosis. These mutations cluster in the DNA-binding Runt domain and are thought to represent loss-of-function mutations, indicating that RUNX1 suppresses T-cell transformation. RUNX1 has been proposed to have tumor suppressor roles in T-cell leukemia homeobox 1/3-transformed human T-ALL cell lines and NOTCH1 T-ALL mouse models. Yet, retroviral insertional mutagenesis screens identify RUNX genes as collaborating oncogenes in MYC-driven leukemia mouse models. To elucidate RUNX1 function(s) in leukemogenesis, we generated Tal1/Lmo2/Rosa26-CreERT2Runx1f/f mice and examined leukemia progression in the presence of vehicle or tamoxifen. We found that Runx1 deletion inhibits mouse leukemic growth in vivo and that RUNX silencing in human T-ALL cells triggers apoptosis. We demonstrate that a small molecule inhibitor, designed to interfere with CBFβ binding to RUNX proteins, impairs the growth of human T-ALL cell lines and primary patient samples. We demonstrate that a RUNX1 deficiency alters the expression of a crucial subset of TAL1- and NOTCH1-regulated genes, including the MYB and MYC oncogenes, respectively. These studies provide genetic and pharmacologic evidence that RUNX1 has oncogenic roles and reveal RUNX1 as a novel therapeutic target in T-ALL.
引用
- Choi A, Illendula A, Pulikkan JA, et al. RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia. Blood. 2017. PMID: 28790107. doi:10.1182/blood-2017-03-775536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。